Stryker ($SYK) and OrthoSensor extended their agreement to co-market Stryker's Triathlon knee system and OrthoSensor's Verasense feedback software for knee-replacement surgery. Verasense offers data to surgeons on soft-tissue balance during the surgery, allowing Triathlon to perform better later on. OrthoSensor, which now has $36 million worth of Series B funding for its knee-balancing software, struck the original deal with Stryker last August, and the FDA-approved Verasense is, as a result, only compatible with the Triathlon device. Release